2021
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Srivastava SP, Srivastava R, Chand S, Goodwin JE. Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease. Pharmaceuticals 2021, 14: 751. PMID: 34451848, PMCID: PMC8398861, DOI: 10.3390/ph14080751.Peer-Reviewed Original ResearchCell typesDiabetic kidney diseaseCOVID-19 patientsSuppression of AMPProtein kinase activationKidney cellsMAS1 receptorCellular homeostasisKidney diseaseKinase activationCell homeostasisAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionTransferase 4Diabetic COVID-19 patientsSyndrome coronavirus 2 infectionCoronavirus 2 infectionAMPK levelsDPP-4 levelsCOVID-19 severityCOVID-19-associated cytokine stormTubular epithelial cellsMesenchymal activationOrgan fibrosisNovel drug therapies
2020
Loss of Mitochondrial Control Impacts Renal Health
Srivastava SP, Kanasaki K, Goodwin JE. Loss of Mitochondrial Control Impacts Renal Health. Frontiers In Pharmacology 2020, 11: 543973. PMID: 33362536, PMCID: PMC7756079, DOI: 10.3389/fphar.2020.543973.Peer-Reviewed Original ResearchImportance of mitochondriaMetabolic shiftMultiple cellular processesDiverse cell typesCell transdifferentiation processMitochondrial biologyMitochondrial controlCellular processesMitochondrial regulationMitochondrial biosynthesisMitochondrial sirtuinsMetabolic networksTransdifferentiation processMitochondrial dysfunctionCell typesMitochondriaKidney cellsTherapeutic targetRegulationFuel preferencePotential leadsCellsBiosynthesisSirtuinsBiology